Next Article in Journal
Evaluating the Effect of Cell Culture on Gene Expression in Primary Tissue Samples Using Microfluidic-Based Single Cell Transcriptional Analysis
Next Article in Special Issue
Retrospective Proteomic Analysis of Cellular Immune Responses and Protective Correlates of p24 Vaccination in an HIV Elite Controller Using Antibody Arrays
Previous Article in Journal
Cancer–Osteoblast Interaction Reduces Sost Expression in Osteoblasts and Up-Regulates lncRNA MALAT1 in Prostate Cancer
Article Menu

Export Article

From the third issue of 2017, Microarrays has changed its name to High-Throughput.

Open AccessReview
Microarrays 2015, 4(4), 520-539; doi:10.3390/microarrays4040520

Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery

1
Statistical Bioinformatics, Department of Medical Statistics, University Medical Center Goettingen, Humboldtallee 32, D-37073 Goettingen, Germany
2
German Cancer Research Center (DKFZ)
*
Author to whom correspondence should be addressed.
Academic Editors: Ulrika Andreasson, Carl A. K. Borrebaeck and Christer Wingren
Received: 19 September 2015 / Revised: 12 October 2015 / Accepted: 20 October 2015 / Published: 3 November 2015
(This article belongs to the Special Issue Antibody Microarrays in Clinical Proteomics)
View Full-Text   |   Download PDF [2772 KB, uploaded 3 November 2015]   |  

Abstract

Mastering the systematic analysis of tumor tissues on a large scale has long been a technical challenge for proteomics. In 2001, reverse phase protein arrays (RPPA) were added to the repertoire of existing immunoassays, which, for the first time, allowed a profiling of minute amounts of tumor lysates even after microdissection. A characteristic feature of RPPA is its outstanding sample capacity permitting the analysis of thousands of samples in parallel as a routine task. Until today, the RPPA approach has matured to a robust and highly sensitive high-throughput platform, which is ideally suited for biomarker discovery. Concomitant with technical advancements, new bioinformatic tools were developed for data normalization and data analysis as outlined in detail in this review. Furthermore, biomarker signatures obtained by different RPPA screens were compared with another or with that obtained by other proteomic formats, if possible. Options for overcoming the downside of RPPA, which is the need to steadily validate new antibody batches, will be discussed. Finally, a debate on using RPPA to advance personalized medicine will conclude this article. View Full-Text
Keywords: cancer; reverse phase protein array; reverse phase protein arrays (RPPA); signaling pathways; immunoassay; antibody cancer; reverse phase protein array; reverse phase protein arrays (RPPA); signaling pathways; immunoassay; antibody
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Wachter, A.; Bernhardt, S.; Beissbarth, T.; Korf, U. Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery. Microarrays 2015, 4, 520-539.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Microarrays EISSN 2076-3905 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top